The Role of the Basolateral and Central Amygdala During Heroin Withdrawal and 3,4-Methylenedioxymethamphetamine Administration

Opioid use disorder involves dependence, withdrawal, and high relapse risk, but the neuroimmune mechanisms in the amygdala during withdrawal are not well understood. In adult male rats given escalating heroin doses over 10 days followed by 24-hour withdrawal, MDMA or saline was administered. Heroin-treated rats showed significant weight loss during withdrawal, confirming dependence, and MDMA did not worsen this effect. TNF-α immunoreactivity showed no effect of heroin withdrawal or MDMA in the central or basolateral amygdala, though a trend in the basolateral amygdala suggests subtle modulation by combined exposure.

Study at a glance

Abstract

Opioid use disorder (OUD) is characterized by dependence, withdrawal, and high relapse risk, yet the neuroimmune mechanisms underlying withdrawal in the amygdala remain poorly understood. This study investigated whether 3,4-methylenedioxymethamphetamine (MDMA) modulates heroin withdrawal–induced neuroinflammation in the central amygdala (CeA) and basolateral amygdala (BLA). Adult male Sprague-Dawley rats received escalating doses of heroin or saline over 10 days, followed by 24-hour withdrawal, during which MDMA or saline was administered. Tissue was collected to examine tumor necrosis factor-alpha (TNF-α) and glial fibrillary acidic protein (GFAP) immunoreactivity, assessing cytokine signaling and astrocytic activation. Heroin-treated animals exhibited significant weight loss during withdrawal, confirming dependence. Furthermore, this effect was not exacerbated by MDMA administration during 0- and 24-hour withdrawal. Analysis of TNF-α immunoreactivity showed no effect of heroin withdrawal or MDMA administration in the CeA or BLA, though a trend in the BLA suggests subtle modulation by combined heroin and MDMA exposure. Analysis of GFAP immunoreactivity revealed region-specific effects; the CeA showed a non-significant trending main effect of MDMA treatment, whereas the BLA displayed a significant interaction between MDMA and heroin, indicating an interactive effect on astrocytic activation. These findings suggest astrocytes in the BLA are particularly sensitive to combined pharmacological effects. Technical limitations, including issues during TNF-α staining, may have impacted expected cytokine differences. Future work incorporating signal amplification, reducing background, and colocalization analyses with neuronal and astrocytic markers is needed to clarify these effects. Overall, this study highlights the differences between cytokine expression and astrocytic activation during heroin withdrawal and suggests that MDMA administration during heroin withdrawal may cause heightened astrocytic reactivity in the BLA.